The quality control product now includes eight opioid drugs or drug metabolites at concentrations above and below assay cutoffs.
Bio-Rad Laboratories has launched an enhanced version of its Liquichek Opiate Control with updated fentanyl target levels optimized for clinically relevant cutoffs across chemistry major platforms.
The enhanced quality control product contains eight opioid drugs or drug metabolites at concentrations above and below assay cutoffs as recommended by the US Substance Abuse and Mental Health Services Administration, other agencies, or reagent manufacturers.
The control is tested by GC/MS, LC/MS/MS, and other methods to confirm the recovery of drug concentration, with representative values provided for screening and confirmatory methods. The update ensures laboratories can meet evolving testing requirements with confidence and precision, according to Bio-Rad.
The Liquichek Opiate Control aims to streamline workflows and deliver validated precision at clinically relevant cutoffs.
The enhanced control is available now from the Hercules, California-based global provider of life science research and clinical diagnostics products.
Photo caption: Liquichek Opiate Control
Photo credit: Bio-Rad Laboratories
